Fitness Trends Fc Protein and Glycoengineered Antibodies Market | Page 3

such as Obinutuzumab (Gazyva), Mogamulizumab (Poteligeo), Atezolizumab (Tecentriq), and
Durvalumab (Imfinzi) have been approved in the U.S. in 2013, 2018, 2016, and 2017
respectively.
Europe is expected to witness significant growth in the global Fc protein and glycoengineered
antibodies market. Factors such as approval for new drugs is expected to drive the Europe’s Fc
protein and glycoengineered antibodies market growth over the forecast period. For instance, in
2018, Kyowa Hakko Kirin Co. Ltd. received an approval from the European Commission to
market the Poteligeo antibody in the European market. It is the first biological product that is
being directed against chemokine receptor 4 (CCR4), which will be used for the treatment of
Sezary syndrome that has been previously treated by systemic therapy. Such new drug
approvals are expected to propel Europe Fc protein and glycoengineered antibodies market
growth over the forecast period.
Global Fc Protein and Glycoengineered Antibodies Market Key Players
Some of the major players operating in the global Fc protein and glycoengineered antibodies
market include Kyowa Hakko Kirin Co. Ltd., Merck KGaA, Boehringer Ingelheim International
GmbH, AstraZeneca Plc, Amgen Inc., Genentech Inc., Five Prime Therapeutics Inc., Celldex
Therapeutics, Clovis Oncology, and TG Therapeutics, Inc.
Request For Customization of Research Report @
https://www.coherentmarketinsights.com/insight/request-customization/2626
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering action-
ready syndicated research reports, custom market analysis, consulting services, and competitive
analysis through various recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: [phone]
Email: [e-mail]